Journal
PEDIATRIC NEPHROLOGY
Volume 33, Issue 5, Pages 779-787Publisher
SPRINGER
DOI: 10.1007/s00467-017-3695-3
Keywords
Acute kidney injury; Acute renal failure; Clinical trials; Therapeutics; Pediatric
Categories
Funding
- NIDDK NIH HHS [P50 DK096418] Funding Source: Medline
Ask authors/readers for more resources
Acute kidney injury (AKI) is a significant source of morbidity and mortality in pediatric patients, affecting more than one quarter of critically ill children. Despite significant need, there are no targeted therapies to reliably prevent or treat AKI. Recent advances in our understanding of renal injury and repair signaling pathways have enabled the development of several targeted pharmaceuticals. Here we review emerging pharmacotherapies for AKI that are currently in clinical trials. Categorized by their general mechanism of action, the therapies discussed include anti-inflammatory agents (recAP, AB103, ABT-719), antioxidants (iron chelators, heme arginate), vasodilators (levosimendan), apoptosis inhibitors (QPI-1002), and repair agents (THR-184, BB-3, mesenchymal stem cells).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available